BRIEF

on Edesa Biotech (NASDAQ:EDSA)

Edesa Biotech to Showcase at Barclays Global Healthcare Conference

Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, announced its participation in the upcoming Barclays 26th Annual Global Healthcare Conference in Miami, Florida, from March 12 to March 14, 2024. The company, known for its focus on developing therapeutics for immuno-inflammatory diseases, looks forward to engaging with attendees and potential investors during the event. Scheduled meetings can be arranged through the conference organizers or directly via the company’s contact email.

Edesa Biotech's pipeline includes several promising drug candidates. Its lead product, EB05 (paridiprubart), is currently in a Phase 3 study targeting Acute Respiratory Distress Syndrome (ARDS). They are also preparing for a Phase 2 study of paridiprubart for pulmonary fibrosis. Additionally, regulatory approval has been granted for a Phase 2 trial of EB06 as a treatment for vitiligo. Moreover, Edesa is developing an sPLA2 inhibitor, EB01, aimed at treating chronic Allergic Contact Dermatitis (ACD).

R. H.

Copyright © 2024 FinanzWire, all reproduction and representation rights reserved. Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.

Click here to consult the press release on which this article is based

See all Edesa Biotech news